Skip to main content
Caplight Logo









HaiHe Biopharma

HaiHe Biopharma

Private
ShanghaiHealthcare & Life Scienceshttps://www.haihepharma.com/

Last Round

Private Placement

Sep 26, 2025

Est. Valuation

$525.3M

Total Funding Raised

$363.8M

Company Overview

HaiHe Biopharma is a biotechnology company that specializes in the discovery, development, and commercialization of innovative anti-tumor drugs.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

oncologysmall-molecule inhibitornon-small cell lung cancerNSCLCbiopharmaceuticaldrug discoverytargeted therapyclinical trialc-MET inhibitorPARP-1 inhibitorMat2A inhibitorbiotechdrug pipelinecancer researchlicensing agreement

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

HaiHe Biopharma Comparables

Compare HaiHe Biopharma with similar companies based on industry and business-model similarity.

HaiHe Biopharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Apollomics
88%
Avistone Pharmaceuticals
86%
HUTCHMED (China) Limited
82%

HaiHe Biopharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Private PlacementSep 26, 2025
IPOMay 28, 2024
Series CJun 1, 2023
IPOSep 22, 2021
StrategicAug 10, 2021
Series B
Jul 27, 2020

Key People

Founding team and executive leadership

Jingwei Liu

Chief Financial Officer

Executive Team

HaiHe Biopharma Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 28, 2024

    $403M raised in IPO round.

  • Sep 22, 2021

    IPO round led by Guotai Junan Securities (Hong Kong) Limited.

HaiHe Biopharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

HaiHe Biopharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about HaiHe Biopharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range29
Year Founded2011
Last FundingSep 26, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?